RealFeedApp Immobazyme cuts Africa's biopharma import bill
South Africa imports 99% of its vaccines and up to 90% of biopharmaceuticals, risking a $1.1 trillion loss in skills and jobs by 2050. Startup Immobazyme is developing low-cost recombinant proteins and enzymes via precision fermentation to reduce reliance on imports.
- Field
- industry news
- What they did
- South African labs and startups are developing technologies to produce affordable biopharmaceuticals locally, aiming to reduce the continent's heavy reliance on imports.
- Why it matters
- This is urgent because Africa imports 99% of its routine vaccines and 70–90% of its biopharmaceuticals, a vulnerability that could cost the continent up to $1.1 trillion in skills and jobs by 2050.
#biopharma#precision fermentation#immobazyme#africa cdc#recombinant proteins
